UNSPSC 51431805: Irbesartan hydrochloride

This classification denotes an angiotensin ii receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3OGC31WUMZ. European Medicines Agency schedules Irbesartan hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB29917. Irbesartan hydrochloride generally arises in the molecular formula C25H28N6O.CLH. The term 'irbesartan hydrochloride' is a European Medicines Agency European Public Assessment Report System designation.

Most nations, for tariff and trade purposes, schedule irbesartan hydrochloride under HS 29332990 and SITC 51573. As of Q4 2014, IRBESARTAN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCCCC1=NC2(CCCC2)C(=O)N1CC3CCC(CC3)C4CCCCC4C5[NH]NNN5.CL.

UNSPSC 51431805 Irbesartan hydrochloride is a Commodity code for a specific pharmaceutical active ingredient used in blood-pressure management therapies. State and local governments procure this and related medications primarily through emergency medical services, pharmacy benefit programs, and institutional healthcare purchasing vehicles. The recent solicitations show that the code captures both direct emergency-response medication procurement—fire rescue units and paramedic services—and broader multi-state cooperative purchasing arrangements for generic pharmaceuticals distributed across state agency networks, educational facilities, and local government health systems.

The issuing-body mix includes fire rescue departments (City of Tampa), state health agencies (Texas Health and Human Services Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota, Oregon, and other participating jurisdictions). Recent activity spans the Southeast, Texas, and Upper Midwest. Representative opportunities include the City of Tampa's sealed-bid IFB for Advanced Life Support Medications with a response date of April 8, 2026 and an estimated contract value of $40,000, which sourced four specific medication line items for Tampa Fire Rescue with nine-month minimum shelf life and ten-day delivery requirements; the Texas HHS Commission's Request for Information (RFI) posted April 3, 2026 exploring direct-to-manufacturer prescription fulfillment strategies outside traditional pharmacy benefit manager channels; and the Minnesota Department of Administration's RFP through MMCAP with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products to supply authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) with contract effectiveness July 1, 2026. The MMCAP procurement weighted price competitiveness at 75 percent of evaluation and imposed a 3 percent administrative fee on all purchases, while the Tampa bid included a 5 percent discount for Small Local Business Enterprise participation capped at $10,000.